Recent News

Managing Breast Cancer in Older Adults: An Updated International Policy Review

Can Serum Levels of Vitamin D at Diagnosis Predict Breast Cancer Prognosis?

Pembrolizumab Combination Receives FDA Approval in Triple-Negative Breast Cancer

FDA Brief: Trilaciclib Plus Chemotherapy Granted Fast Track Designation in Triple-Negative Breast Cancer

Early Results for Novel Combination in Metastatic Breast Cancer

Early-Phase Trials of Novel Antibody-Drug Conjugate in HER2-Overexpressed Solid Tumors

Pooled Analysis of HER2-Targeting Antibody-Drug Conjugate in Metastatic Breast Cancer

Fulvestrant With or Without Venetoclax in Locally Advanced or Metastatic Breast Cancer

Body Mass Index and Breast Cancer Outcomes by Racial Ancestry

Fam-trastuzumab Deruxtecan-nxki for Metastatic Breast Cancer With Brain Metastases

ASCO 2021: Neoadjuvant Talazoparib Active in Germline BRCA1/2-Mutated HER2-Negative Breast Cancer

Patient With Breast Cancer Successfully Treated With Immunotherapy in Thailand Hospital

ASCO 2021: MONALEESA-3 Survival Update of Ribociclib/Fulvestrant for Advanced Breast Cancer

Updated ASCO Guideline for Managing Hereditary Breast Cancer

ASCO 2021: Long-Term Survival With Palbociclib Plus Fulvestrant in Advanced Breast Cancer

Treatment Implications of Breast Tumors’ Switch to HER2-Low Status in Recurrence

Implications of Symptom Burden Among Breast Cancer Survivors

ASCO 2021: Adjuvant Durvalumab Treatment for Triple-Negative Breast Cancer

ASCO 2021: Novel CDK4/6 Inhibitor Plus Fulvestrant Focus of Phase III Trial in Advanced Breast Cancer

ASCO 2021: Adjuvant Capecitabine Versus Platinum-Based Chemotherapy for Residual Triple-Negative Breast Cancer

ASCO 2021: COVID-19 Outcomes and Breast Cancer by Racial/Ethnic Group

Androgen Receptor–Targeting Agent Under Study in Metastatic Disease

ASCO 2021: Survival Outcomes With De-escalated Neoadjuvant Treatment of Early Breast Cancer

ASCO 2021: OlympiA Trial of Adjuvant Olaparib After Chemotherapy for Early-Stage Breast Cancer

ESMO Breast 2021: Atezolizumab Plus Carboplatin for Metastatic Invasive Lobular Cancer

ESMO Breast 2021: Distinct Gene Signatures Associated With Pathologic Complete Response

ESMO Breast 2021: Does Clinical Benefit From Endocrine Therapy Differ by Risk Group?

Adding Oral Alisertib to Weekly Paclitaxel for Metastatic Breast Cancer

ESMO Breast 2021: Clinical Role of RAD51 Testing in Triple-Negative Breast Cancer

ESMO Breast 2021: Safety Outcomes With Abemaciclib Plus Endocrine Therapy in Early Breast Cancer

Eribulin and Pembrolizumab Combination in Triple-Negative Breast Cancer

ASBrS 2021: Can Medicaid Expansion Improve Disparities in Breast Reconstruction?

APHINITY Trial Update: Adjuvant Pertuzumab-Based Therapy in Early HER2-Positive Breast Cancer

Treadmill and T Cells: Can Exercise Enhance Immune Responses in Breast Cancer?

Can Healthy Plant-Based Diets Decrease the Risk of Breast Cancer?

Predicting Response to Combination Therapies for Breast Cancer Brain Metastases

AACR 2021: Can Gut Microbiota Influence Treatment Response in Metastatic Breast Cancer

Distant Lymph Node Metastases From Breast Cancer: A Regional Disease?

AACR 2021: Using ctDNA Changes to Predict Response to Palbociclib-Based Therapy for Breast Cancer

AACR 2021: Talazoparib/Carboplatin Under Study in Triple-Negative Breast Cancer

Fixed-Dose Pertuzumab-Based Regimen Under Study in FeDeriCa Trial

Could Regularly Drinking Sugar-Sweetened Soda Be Linked to Breast Cancer Mortality?

Is Surveillance Mammography Necessary in Older Breast Cancer Survivors?

AACR 2021: Neratinib Plus Fulvestrant for HER2-Mutant Metastatic Breast Cancer

FDA Brief: Cryoablation Technology Receives Breakthrough Device Designation in Breast Cancer

Are Type 2 Diabetes and Metformin Use Associated With Breast Cancer Risk?

Sacituzumab Govitecan-hziy Receives Regular FDA Approval for Triple-Negative Breast Cancer

FDA Grants Two New Breakthrough Device Designations for MRD Testing

Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel

KEYNOTE-355 Update on Pembrolizumab in Triple-Negative Breast Cancer

Risk of Breast Cancer in Common Drugs for Diabetes and Obesity

Endocrine Therapy for Men With Breast Cancer: Estradiol Levels, Sexual Function, and Quality of Life

Company Announces Discontinuation of Development of Oral Taxane Tesetaxel

Miami Breast Cancer Conference 2021: DESTINY-Breast01 Trial Update on Trastuzumab Deruxtecan-nxki

Miami Breast Cancer Conference 2021: Neratinib-Based Regimens for CNS Metastases

Are Most Women Who Forgo Reconstruction After Mastectomy Satisfied With the Results?

Miami Breast Cancer Conference 2021: Tolerability of Capecitabine in U.S. Patients With Triple-Negative Breast Cancer

Miami Breast Cancer Conference 2021: Comparing Radiolabeled Mapping Agents in Identifying Sentinel Lymph Nodes

Margetuximab-cmkb Versus Trastuzumab in ERBB2-Positive Advanced Breast Cancer

Miami Breast Cancer Conference 2021: Neoadjuvant Chemotherapy in Minority Groups

PD-L1 mRNA Expression and Treatment Response in Triple-Negative Breast Cancer

FDA Flags Safety Concerns for Oral Paclitaxel Plus Encequidar in Treatment of Breast Cancer

ASCO Guideline: Focus on Optimal Neoadjuvant Therapy for Breast Cancer

Can Androgen Receptor Agonists Improve Outcomes in Estrogen Receptor–Positive Breast Cancer?

Neoadjuvant Regimens Compared in Advanced Operable Breast Cancer

COVID-19 and Breast Cancer: Protective Role for Antiestrogen Therapies?

MONALEESA-7 Update: Ribociclib Plus Endocrine Therapy for Advanced Breast Cancer

Phase II Basket Trial of Dual HER2-Targeted Therapy in Metastatic Breast Cancer

World Health Organization Reports Breast Cancer Now the Most Common Type of Cancer Worldwide